By the end of 2028, most new scientific papers studying how ibogaine works will focus on a specific brain circuit—the mPFC (medial prefrontal cortex) and its glutamate chemistry—rather than older theories about opioid receptors. This shift reflects cleaner scientific evidence and simpler explanations that drug companies prefer, though the field changes slowly.
Operationalized as: >50% of new preclinical ibogaine/noribogaine mechanistic papers published in 2028 cite mPFC glutamate modulation as primary hypothesis, as measurable via PubMed. The scientific logic is sound—mPFC glutamate is a cleaner, translationally compelling story than opioid receptor modulation. However, fields shift slowly, opioid receptor framing has deep roots, and a single alcohol drinking paper is insufficient to establish consensus. 2028 is plausible but not certain. Confidence trimmed from 0.74.